NK cells, as key effector cells of the innate immune system, can recognize and kill tumor cells without prior sensitization, exerting their effects by releasing perforin, granzyme, and secreting cytokines such as interferon-γ (IFN-γ) (9), which indicate CAR-NK cells offer significant promise for tumor immunotherapy. The gene discussed is PRF1; the disease is neoplasm.